Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Trial Profile

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Aspirin; Hydroxycarbamide
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms PEGHU-Phase3
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2017 Planned End Date changed from 1 Jun 2024 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top